In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has ...

Flu vaccines are crucial tools in protecting public health by reducing the risk of influenza illness and its complications.

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

The experimental mRNA vaccine prevented 60% to 67% of flu infections, while the conventional vaccine prevented 44% to 54% of ...

Cell-based influenza vaccines were superior to egg-based vaccines across patient populations during a recent influenza season ...

For people younger than 65, U.S.-licensed flu vaccines had an estimated effectiveness of 44% to 54% that season. Among those who completed a 6-month follow-up, the mRNA vaccine had a relative efficacy ...

An expert committee that advises the Centers for Disease Control and Prevention on vaccines is meeting for the first time since Health Secretary Robert F. Kennedy Jr. abruptly replaced the committee’s ...

Subclade k has been circulating in Asia and in Europe, and it might already be in the United States, experts said.